Leading UK Pharmacies trust Deltera
Our UK Pharmacist-approved Wegovy Tablets PGD (Patient Group Direction) enables accredited community pharmacies to deliver a complete, private weight management service. Wegovy (semaglutide) tablets offer a daily oral treatment option for adult weight loss, helping patients manage appetite and achieve sustainable health goals alongside diet and lifestyle modifications. Integrated directly into the Deltera platform, this PGD provides complete clinical protocols, eligibility assessment criteria, titration schedules, and automated pre-screening workflows to ensure safe, efficient, and fully compliant in-pharmacy supply.
A Fully Digital Clinical Platform
Integrated Bookings and Payments
Secure & Connected Patient Records
Ditch the paperwork with secure digital records. Deltera automatically shares treatment summaries with the patient’s and sends the required notification to their GP instantly.
Training and Eligibility Requirements
To ensure clinical safety and regulatory compliance, all practitioners using this PGD must meet the following professional standards:
- Professional Registration: Must be a registered healthcare professional (e.g., Pharmacist) with a valid GPhC or PSNI registration and personal professional indemnity insurance.
- Clinical Competency: Practitioners must be self-certified as competent in the specific clinical area covered by this PGD and stay up to date with relevant national guidelines (e.g., The Green Book or NICE clinical summaries).
- Mandatory Training: Current certification in Basic Life Support (BLS) and the management of anaphylaxis is required for all injectable services.
- PGD Authorisation: The practitioner must have read and signed the PGD document within the Deltera Clinical Dashboard, with the authorisation counter-signed by the designated organisational lead or Superintendent.
- Premises Standards: Services must be conducted in a private consultation room that meets national standards for patient confidentiality and clinical safety.
Speak to the clinicians behind the platform
We understand the complexities of PGDs and clinical governance in the UK. Schedule a meeting with our team to see how we can help you navigate the changing landscape of community pharmacy.
Access related PGDs
FAQs
What is the Wegovy Tablets PGD?
The Wegovy Tablets PGD is a legal clinical framework that allows trained, registered pharmacists to supply oral semaglutide (Wegovy tablets) directly to eligible patients for weight loss without requiring a traditional GP prescription.
Who is eligible to receive Wegovy tablets under this pharmacy PGD?
Adult patients aged 18 to 75 with a Body Mass Index (BMI) of 30 kg/m² or higher, or a BMI of 27 kg/m² or higher with at least one weight-related comorbidity (such as hypertension or dyslipidaemia), following a completed clinical consultation and pre-screen.
How do Wegovy tablets differ from injectable weight loss treatments?
Wegovy tablets contain semaglutide in a daily oral format taken on an empty stomach. They act as a GLP-1 receptor agonist to regulate appetite and increase feelings of fullness, offering a highly effective alternative for patients seeking weight management without subcutaneous injections.
How is this PGD managed and signed off for my pharmacy group?
The PGD is fully managed through the Deltera Superintendent Dashboard. It includes automated consultation recording, digital pre-screening forms, and instant online superintendent signing to keep your estate compliant.
Still have questions?
Our team are here to support you.
Discover the Deltera Platform
The Deltera Platform digitalises your private pharmacy services, providing the complete pharmacy software package to offer a full range of Patient Group Directions (PGDs). Gain the oversight and efficiency you need to thrive.
